Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer
- 1 May 2009
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Urology
- Vol. 19 (3), 221-226
- https://doi.org/10.1097/mou.0b013e32832a2d10
Abstract
To delineate how recent findings on prostate-specific antigen (PSA) can improve prediction of risk, detection, and prediction of clinical endpoints of prostate cancer (PCa). The widely used PSA cut-point of 4.0 ng/ml increasingly appears arbitrary, but no cut-point achieves both high sensitivity and high specificity. The accuracy of detecting PCa can be increased by additional predictive factors and a combinations of markers. Evidence implies that a panel of kallikrein markers improves the specificity and reduces costs by eliminating unnecessary biopsies. Large, population-based studies have provided evidence that PSA can be used to predict PCa risk many years in advance, improve treatment selection and patient care, and predict the risk of complications and disease recurrence. However, definitive evidence is currently lacking as to whether PSA screening lowers PCa -specific mortality. PSA is still the main tool for early detection, risk stratification, and monitoring of PCa. However, PSA values are affected by many technical and biological factors. Instead of using a fixed PSA cut-point, using statistical prediction models and considering the integration additional markers may be able to improve and individualize PCa diagnostics. A single PSA measurement at early middle age can predict risk of advanced PCa decades in advance and stratify patients for intensity of subsequent screening.Keywords
This publication has 89 references indexed in Scilit:
- What are the Factors Associated With Short Prostate Specific Antigen Doubling Time After Radical Prostatectomy? A Report From the SEARCH Database GroupJournal of Urology, 2008
- Does Prostate Growth Confound Prostate Specific Antigen Velocity? Data From the Baltimore Longitudinal Study of AgingJournal of Urology, 2008
- Evaluation of molecular forms of prostate‐specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomyInternational Journal of Cancer, 2008
- [-2]Proenzyme Prostate Specific Antigen for Prostate Cancer Detection: A National Cancer Institute Early Detection Research Network Validation StudyJournal of Urology, 2008
- A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, SwedenBMC Medicine, 2008
- Prostate Specific Antigen Working Group Guidelines on Prostate Specific Antigen Doubling TimeJournal of Urology, 2008
- Limitations of Prostate Specific Antigen Doubling Time Following Biochemical Recurrence After Radical Prostatectomy: Results From the SEARCH DatabaseJournal of Urology, 2008
- Population-Based Case-Control Study of PSA and DRE Screening on Prostate Cancer MortalityUrology, 2007
- Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trialBritish Journal of Cancer, 2007
- Detection of Life-Threatening Prostate Cancer With Prostate-Specific Antigen Velocity During a Window of CurabilityJNCI Journal of the National Cancer Institute, 2006